Clear Sky Medical Diagnostics - Health Economic Assessment for monitoring the side effects of Parkinson's medication and informing treatment

帕金森病（PD）仅在英国就影响了大约120，000人，并且随着人们寿命的延长，预计在未来十年内将急剧增加。治疗帕金森病症状最有效的药物是左旋多巴，但大约90%的患者服用10年或更长时间后会出现不自主运动，称为运动障碍。这些运动是残疾的主要来源，严重影响患者的生活质量，并发症包括不受控制的运动障碍，福尔斯和骨折。财务影响是显着的;豪瑟和Pahwa报告“在运动障碍发作后的一年中，总体治疗费用增加了7795美元，PD相关费用增加了4194美元。”运动障碍的管理是特别困难的，因为它可能会发生很多次，每天和准确的监测方法是不可用的。目前，医生依靠病人的描述，或者在严重的情况下，病人住院几天来监测症状，并相应地调整药物。由于目前很难准确测量运动障碍，因此对患者药物的改变通常无效。Clear Sky Medical Diagnostics（CSMD）开发了一种独特的技术，该技术与当前的监测方法相比具有许多优势，特别是专注于测量的速度和客观性。小规模的临床试验已经进行，但NHS和国际卫生组织的经济效益尚未记录在案。约克健康经济联合会已经接触，以列出潜在的财政节省，并衡量的质量调整生命年（质量调整生命年），一个标准的衡量标准，评估健康技术的基础上改善病人的福祉的技术方面的好处。提供这种健康经济评估，以及已经到位的临床数据将允许CSMD将这项技术推向市场。

Parkinson’s disease (PD) affects approximately 120,000 people in the UK alone and isprojected to increase dramatically over the next decade as people live longer. The mosteffective form of treatment for PD symptoms is a drug called levodopa, but approximately90% patients who take it for ten years or more develop involuntary movements calleddyskinesia. These movements are a major source of disability and severely affect the patient’squality of life with complications of uncontrolled dyskinesia including falls and fractures.Financial implications are significant; Hauser and Pahwa report “In the year following onsetof dyskinesia, overall treatment costs increase by $7795 and PD-related costs increased by$4194 pa”. Management of dyskinesia is particularly difficult as it may occur many times perday and an accurate method of monitoring is not available. Currently, physicians rely onpatients’ descriptions or in severe cases patients are admitted to hospital for several days tomonitor symptoms and adjust their medication accordingly. Because it is currently difficult tomeasure dyskinesia accurately, the changes to the patient’s medication can often beineffective.Clear Sky Medical Diagnostics (CSMD) has developed a unique technology, which has anumber of advantages over current monitoring approaches, focussing particularly on the speedand objectivity of the measurement. Small scale clinical trials have taken place, but theeconomic benefits for the NHS and international health organisations are as yetundocumented. York Health Economic Consortium has been approached in order to set outthe potential financial savings, and to also measure the benefit of the technology in terms ofQALY (quality adjusted life years), a standard measurement for assessing health technologiesbased on improvement in patients’ wellbeing. Provision of this health economic assessment,alongside the clinical data already in place will allow CSMD to go to market with thistechnology.